Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Salmonella enterica serovar typhi ZH9

A formulation containing a live-attenuated strain of the bacterium Salmonella typhi, with potential immunomodulating and antineoplastic activities. Upon administration of Salmonella enterica serovar Typhi ZH9, the Salmonella in ZH9 may cause a Salmonella-induced systemic reprogramming of myeloid cells within the tumor microenvironment (TME). This enhances the recruitment of innate and adaptive immune cells, including the upregulation of co-stimulatory and major histocompatibility (MHC) molecules on dendritic cells (DCs), natural killer (NK) cells, CD4+ and CD8+ T cells, monocytes, and macrophages. This may alleviate immune suppression, restore immune fitness and tissue immunosurveillance and re-activate an anti-tumor immune response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:M01ZH 09
M01ZH-09
M01ZH09
ZH 9
ZH-9
ZH9
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search